SCHEMBL2351071

SCHEMBL2351071

COC(=O)CCc1ccc(OC2c3cc(C)ccc3CC2(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
EPHX2 P34913 1/20 0.38
ALDH1A1 P00352 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
KMT2A Q03164 3/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
F2RL1 P55085 1/20 0.36
MEN1 O00255 1/20 0.34
BACE1 P56817 1/20 0.34
VDR P11473 1/20 0.34
PPARD Q03181 1/20 0.34
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347895 0.90 F2RL1 (0.42) LMNAMAPTEPHX2ALDH1A1TDP1
SCHEMBL2353768 0.89 PPARG (0.44) LMNAL3MBTL1PPARG
SCHEMBL2347885 0.88 EPHX2 (0.38) LMNAMAPTEPHX2ALDH1A1ADRB2
SCHEMBL1744972 0.87 EPHX2 (0.39) LMNAMAPTEPHX2ALDH1A1ADRB2
SCHEMBL2351032 0.80 FFAR1 (0.47) LMNAMAPTL3MBTL1F2RL1
SCHEMBL2354270 0.77 FFAR1 (0.48) LMNAL3MBTL1PPARG
SCHEMBL1745046 0.75 FFAR1 (0.48) LMNAL3MBTL1EPHX2
SCHEMBL1745539 0.75 FFAR1 (0.40) LMNAMAPTL3MBTL1ALDH1A1TDP1
SCHEMBL15679161 0.72 HRH3 (0.40) EPHX2ALDH1A1ADRB2ADRB1KMT2A
SCHEMBL2569441 0.71 L3MBTL1 (0.55) LMNAMAPTL3MBTL1EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 LMNA 4000/4885MAPT 4788/4885L3MBTL1 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.